Apricus Biosciences

Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that has an approved product, Vitaros, for the treatment of ED.

Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that has an approved product, Vitaros, for the treatment of ED. Vitaros is approved in Europe and Canada and will be commercialized by Apricus’ marketing partners, which include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), and Bracco SpA. Femprox, the Company’s product candidate for the treatment of FSAID, has successfully completed a nearly 400-subject proof-of-concept study.